FR2706771A1 - Formula for the treatment of certain cancers. - Google Patents

Formula for the treatment of certain cancers. Download PDF

Info

Publication number
FR2706771A1
FR2706771A1 FR9307805A FR9307805A FR2706771A1 FR 2706771 A1 FR2706771 A1 FR 2706771A1 FR 9307805 A FR9307805 A FR 9307805A FR 9307805 A FR9307805 A FR 9307805A FR 2706771 A1 FR2706771 A1 FR 2706771A1
Authority
FR
France
Prior art keywords
formulation according
vitamin
catalyst
organotherapy
officinalis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9307805A
Other languages
French (fr)
Other versions
FR2706771B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9307805A priority Critical patent/FR2706771A1/en
Publication of FR2706771A1 publication Critical patent/FR2706771A1/en
Application granted granted Critical
Publication of FR2706771B1 publication Critical patent/FR2706771B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Abstract

The invention relates to a synergistic formula composed of different constituents all based on natural products, all affording qualities in combating certain forms of cancer. The formula consists of essential oils known for their anticancer action, an antibiotic of vegetable origin, a plant used in its entirety in herbal medicine, trace elements, a vitamin, two stimulants of the immune system, ingredients used in organotherapy and a catalyst.

Description

LA PRESENTE INVENTION CONCERNE LA DECOUVERTE D'UNE FORMULE POUR TRAITER
CERTAINS CANCERS.THIS INVENTION CONCERNS THE DISCOVERY OF A TREATMENT FORMULA
SOME CANCERS.

CETTE MALADIE, QUALIFIEE DE "LONGUE MALADIE", FAIT MOURIR ENCORE DE NOS
JOURS UNE QUANTITE IMPORTANTE D'INDIVIDUS, SURTOUT CEUX VIVANT DANS LES
PAYS DITS RICHES: EN EUROPE, EN AMERIQUE DU NORD PRINCIPALEMENT.THIS DISEASE, CALLED "LONG DISEASE", STILL DIES OUR
DAYS A SIGNIFICANT QUANTITY OF INDIVIDUALS, ESPECIALLY THOSE LIVING IN THE
RICH COUNTRIES: IN EUROPE, IN NORTH AMERICA MAINLY.

L'EXCES DE VIANDE, DE GRAISSE D'ORIGINE ANIMALE, D'ALCOOL, DE TABAC,SONT
DES FACTEURS PREDISPOSANT AU DEVELOPPEMENT D'UN CANCER.EXCESS MEAT, FAT OF ANIMAL ORIGIN, ALCOHOL, TOBACCO, ARE
FACTORS PREDISPOSING TO THE DEVELOPMENT OF CANCER.

IL Y A AUSSI UNE POPULATION A RISQUE ET DES PROFESSIONS EXPOSANT CERTAINS
INDIVIDUS A DES RADIATIONS QUI ENGENDRERONT, A COURT OU A MOYEN TERME,
CERTAINES FORMES DE CANCERS.THERE IS ALSO A POPULATION AT RISK AND PROFESSIONS EXPOSING SOME
INDIVIDUALS TO RADIATIONS THAT WILL CAUSE, SHORT OR MEDIUM-TERM,
CERTAIN FORMS OF CANCER.

HEUREUSEMENT, LA SCIENCE EST ARRIVEE DE NOS JOURS A GUERIR ENVIRON UN
CANCER SUR DEUX.Luckily, science has arrived today to heal around one
CANCER ON TWO.

IL RESTE CEPENDANT 50% DE CAS POUR LESQUELS IL FAUT METTRE EN OEUVRE UNE
THERAPEUTIQUE DIFFERENTE, C'EST CE QUE NOUS IMPOSE LA SIMPLE LECTURE DES
STATISTIQUES ET NOTRE INVENTION CONSISTE A METTRE A LA DISPOSITION D'UN
LABORATOIRE DE FABRICATION, UNE FORMULE ANTI-CANCER A BASE DE PRODUITS
NATURELS, SANS RISQUE D'EFFETS IATROGENES.HOWEVER, 50% OF CASES REMAIN FOR WHICH IT IS NECESSARY TO IMPLEMENT A
DIFFERENT THERAPEUTICS, THAT IS WHAT THE SIMPLE READING OF
STATISTICS AND OUR INVENTION CONSISTS OF MAKING AVAILABLE TO A
LABORATORY OF MANUFACTURE, AN ANTI-CANCER FORMULA BASED ON PRODUCTS
NATURAL, WITHOUT RISK OF IATROGENIC EFFECTS.

CETTE FORMULE CONCUE PRINCIPALEMENT A BASE D'HUILES ESSENTIELLES DONT
CHACUNE A SES VERTUS PHARMACODYNAMIQUES PROPRES, MAIS DONT LE MELANGE
FAVORISE UNE SYNERGIE PERMETTANT UNE REPONSE CONTRE LA MALADIE.THIS FORMULA MAINLY BASED ON ESSENTIAL OILS OF WHICH
EACH HAS ITS OWN PHARMACODYNAMIC PROPERTIES, BUT OF WHICH THE MIXTURE
PROMOTES SYNERGY FOR A RESPONSE AGAINST ILLNESS.

LA PRESENTE INVENTION VISE AINSI A FOURNIR DES MOYENS NON ENCORE UTILISES
A CE JOUR, MAIS OFFRANT TOUTES LES QUALITES DE CHOIX DANS LA LUTTE CONTRE
CERTAINES FORMES DE CANCERS.THE PRESENT INVENTION ALSO AIMS AT PROVIDING MEANS NOT YET USED
TO DATE, BUT OFFERING ALL THE QUALITIES OF CHOICE IN THE FIGHT AGAINST
CERTAIN FORMS OF CANCER.

L'INVENTION SE RESUME, DE FACON GENERALE, EN UN MELANGE D'HUILES ESSEN
TIELLES DONT LES POURCENTAGES VARIENT ENTRE 0,45% ET 4,80% DE CHACUN DES
COMPOSANTS SUIVANTS: ALLIUM SATIVUM, ANDROPOGON CITRATUS, EUGENIA CARYO
PHYLATA, ROSA CENTIFOLIA DAMASCENA, THUYA OCCIDENTALIS, PELARGONIUM ODORAN
TISSIMUM, CUPRESSUS SEMPERVIRENS, ARTEMISIA DRACUNCULUS, CYMBOPOGON MARI
TINI, CITRUS LIMONUM, ROSMARINUS OFFICINALIS, SATUREIA HORTENSIS OU SATU
REIA MONTANA, SALVIA OFFICINALIS, THYMUS VULGARIS, HYSOPUS OFFICINALIS,
JUNIPERUS COMMUNIS.THE INVENTION CAN BE SUMMARIZED, IN GENERAL, INTO A MIXTURE OF ESSEN OILS
THOSE OF WHICH THE PERCENTAGES VARY BETWEEN 0.45% AND 4.80% OF EACH
FOLLOWING COMPONENTS: ALLIUM SATIVUM, ANDROPOGON CITRATUS, EUGENIA CARYO
PHYLATA, ROSA CENTIFOLIA DAMASCENA, THUYA OCCIDENTALIS, PELARGONIUM ODORAN
TISSIMUM, CUPRESSUS SEMPERVIRENS, ARTEMISIA DRACUNCULUS, CYMBOPOGON MARI
TINI, CITRUS LIMONUM, ROSMARINUS OFFICINALIS, SATUREIA HORTENSIS OR SATU
REIA MONTANA, SALVIA OFFICINALIS, THYMUS VULGARIS, HYSOPUS OFFICINALIS,
COMMUNISED JUNIPERUS.

EN D'AUTRES TERMES, L'INVENTION A POUR OBJET UN MELANGE ANTI-CANCER PUIS
SANT PAR LA SELECTION MEME DES HUILES ESSENTIELLES QUI LE COMPOSENT, RE
CONNUES POUR LEUR EFFET SUR LES TISSUS CANCEREUX.IN OTHER TERMS, THE INVENTION SUBJECTS AN ANTI-CANCER MIXTURE THEN
HEALTH BY EVEN SELECTION OF THE ESSENTIAL OILS THAT MAKE IT UP, RE
KNOWN FOR THEIR EFFECT ON CANCER TISSUES.

LA PRESENTE INVENTION FAIT INTERVENIR EGALEMENT UN ANTIBIOTIQUE D'ORIGINE
VEGETALE: L'ALLICINE, AINSI QUE DES OLIGO-ELEMENTS: ZINC, CHROME, CALCIUM,
MAGNESIUM, FER, NICKEL, GERMANIUM, SELENIUM; UNE VITAMINE: LA VITAMINE E,
L'UTILISATION TOTALE D'UNE PLANTE: LA MONARDE; AINSI QUE DEUX STIMULANTS
DU SYSTEME IMMUNITAIRE: LE COLOSTRUM; DES BIOFLAVONOIDES; DE L'ORGANOTHE
RAPIE: PARATHYROIDE; UN CATALYSEUR: LE THIOSULFATE DE NH4.THIS INVENTION ALSO INVOLVES AN ORIGINAL ANTIBIOTIC
PLANT: ALLICIN, AS WELL AS TRACE ELEMENTS: ZINC, CHROME, CALCIUM,
MAGNESIUM, IRON, NICKEL, GERMANIUM, SELENIUM; A VITAMIN: VITAMIN E,
TOTAL USE OF A PLANT: MONARDE; AS WELL AS TWO STIMULANTS
OF THE IMMUNE SYSTEM: THE COLOSTRUM; BIOFLAVONOIDS; ORGANOTHE
RAPIE: PARATHYROID; A CATALYST: NH4 THIOSULFATE.

LA PRESENTE INVENTION REUNIT DONC UN MELANGE ANTI-CANCER COMPOSE D'HUILES
ESSENTIELLES DONT LA SYNERGIE EST HAUTEMENT PERFORMANTE, ASSOCIE A UN
ANTIBIOTIQUE D'ORIGINE VEGETALE, A DES OLIGO-ELEMENTS, AINSI QU'A UNE PLANTE-DANS SA TOTALITE PHYTOTHERAPEUTIQUE, A DEUX STIMULANTS DU SYSTEME
IMMUNITAIRE, A DE L'ORGANOTHERAPIE ET ENFIN A UN CATALYSEUR.THIS INVENTION COMBINES AN ANTI-CANCER MIXTURE COMPOSED OF OILS
ESSENTIALS WITH HIGHLY PERFORMING SYNERGY, ASSOCIATED WITH
ANTIBIOTIC OF PLANT ORIGIN, WITH OLIGO-ELEMENTS, AS WELL AS A PLANT-IN ITS PLANT PHYTOTHERAPEUTIC, WITH TWO SYSTEM STIMULANTS
IMMUNE, TO ORGANOTHERAPY AND FINALLY TO A CATALYST.

LA PRESENTE INVENTION EST UNE FORMULATION DE TRES HAUTE PERFORMANCE DANS
LE TRAITEMENT DE CERTAINS CANCERS. THE PRESENT INVENTION IS A VERY HIGH PERFORMANCE FORMULATION IN
TREATMENT OF CERTAIN CANCERS.

Claims (9)

REVENDICATIONS VULGARIS, HYSOPUS OFFICINALIS, JUNIPERUS COMMUNIS. VULGARIS, HYSOPUS OFFICINALIS, JUNIPERUS COMMUNIS. SATUREIA HORTENSIS OU SATUREIA MONTANA, SALVIA OFFICINALIS, THYMUS SATUREIA HORTENSIS OR SATUREIA MONTANA, SALVIA OFFICINALIS, THYMUS CULUS, CYMBOPOGON MARITINI, CITRUS LIMONUM, ROSMARINUS OFFICINALIS, CULUS, CYMBOPOGON MARITINI, CITRUS LIMONUM, ROSMARINUS OFFICINALIS, PELARGONIUM ODORANTISSIMUM, CUPRESSUS SUPERVIRENS, ARTEMISIA DRACUN PELARGONIUM ODORANTISSIMUM, CUPRESSUS SUPERVIRENS, ARTEMISIA DRACUN EUGENIA CARYOPHYLATA, ROSA CENTIFOLIA DAMASCENA, THUYA OCCIDENTALIS, EUGENIA CARYOPHYLATA, ROSA CENTIFOLIA DAMASCENA, THUYA OCCIDENTALIS, CUN DES COMPOSANTS SUIVANTS: ALLIUM SATIVUM, ANDROPOGON CITRATUS, ONE OF THE FOLLOWING COMPONENTS: ALLIUM SATIVUM, ANDROPOGON CITRATUS, MELANGE D'HUILES ESSENTIELLES COMPREND ENTRE 0,45% ET 4,80% DE CHA MIXTURE OF ESSENTIAL OILS COMPRISES BETWEEN 0.45% AND 4.80% CHA H - UN CATALYSEUR, H - A CATALYST, 2) FORMULATION SELON LA REVENDICATION 1(A) CARACTERISEE EN CE QUE LE2) FORMULATION ACCORDING TO CLAIM 1 (A) CHARACTERIZED IN THAT THE G - DE L'ORGANOTHERAPIE, G - ORGANOTHERAPY, F - DES STIHLJLS DU SYSTEME IMMUNITAIRE, F - STIHLJLS OF THE IMMUNE SYSTEM, E - DE LA PHYTOTHERAPIE,  E - PHYTOTHERAPY, D - UNE VITAMINE, D - A VITAMIN, C - DES OLIGO-ELEMENTS, C - OLIGO-ELEMENTS, B - UN ANTIBIOTIQUE D'ORIGINE VEGETALE, B - AN ANTIBIOTIC OF PLANT ORIGIN, A - UN MELANGE D'HUILES ESSENTIELLES, A - A MIXTURE OF ESSENTIAL OILS, RISEE EN CE QU'ELLE CONTIENT: RISEE IN WHAT IT CONTAINS: 1) LA FORMULATION POUR LE TRAITEMENT DE CERTAINS CANCERS EST CARACTE 1) THE FORMULATION FOR THE TREATMENT OF CERTAIN CANCERS IS CHARACTER 3) FORMULATION SELON LA REVENDICATION 1(B) CARACTERISEE EN CE QUE L'AN3) FORMULATION ACCORDING TO CLAIM 1 (B) CHARACTERIZED IN THAT THE YEAR TIBIOTIQUE D'ORIGINE VEGETALE EST L'ALLICINE. TIBIOTIC OF PLANT ORIGIN IS ALLICIN. 4) FORMULATION SELON LA REVENDICATION 1(C) CARACTERISEE EN CE QUE CHA4) FORMULATION ACCORDING TO CLAIM 1 (C) CHARACTERIZED IN THAT CHA CUN DES OLIGO-ELEMENTS EST: LE CHROME, LE CALCIUM, LE MAGNESIUM, LE ONE OF THE TRACE ELEMENTS IS: CHROME, CALCIUM, MAGNESIUM, ZINC, LE FER, LE NICKEL, LE GERMANIUM, LE SELENIUM. ZINC, IRON, NICKEL, GERMANIUM, SELENIUM. 5) FORMULATION SELON LA REVENDICATION 1(D) CARACTERISEE EN CE QUE LA5) FORMULATION ACCORDING TO CLAIM 1 (D) CHARACTERIZED IN THAT THE VITAMINE EST LA VITAMINE E. VITAMIN IS VITAMIN E. 6) FORMULATION SELON LA REVENDICATION 1(E) CARACTERISEE EN CE QUE LA6) FORMULATION ACCORDING TO CLAIM 1 (E) CHARACTERIZED IN THAT THE PLANTE TOTALE EN PHYTOTHERAPIE EST LA MONADE.  TOTAL PLANT IN PHYTOTHERAPY IS THE MONADE. 7) FORMULATION SELON LA REVENDICATION 1(F) CARACTERISEE EN CE QUE LES7) FORMULATION ACCORDING TO CLAIM 1 (F) CHARACTERIZED IN THAT THE DEUX STIMULANTS DU SYSTEME IMMUNITAIRE SONT LE COLOSTRUM ET LES BIO TWO STIMULANTS OF THE IMMUNE SYSTEM ARE COLOSTRUM AND BIO FLAVONOIDES. FLAVONOIDES. 8) FORMULATION SELON LA REVENDICATION 1(G) CARACTERISEE EN CE QUE LE8) FORMULATION ACCORDING TO CLAIM 1 (G) CHARACTERIZED IN THAT THE COMPOSANT D'ORGANOTHERAPIE EST: PARATHYROIDE. COMPONENT OF ORGANOTHERAPY IS: PARATHYROID. 9) FORMULATION SELON LA REVENDICATION 1(H) CARACTERISEE EN CE QUE LE9) FORMULATION ACCORDING TO CLAIM 1 (H) CHARACTERIZED IN THAT THE CATALYSEUR EST LE THIOSULFATE DE NH4.  CATALYST IS NH4 THIOSULFATE.
FR9307805A 1993-06-21 1993-06-21 Formula for the treatment of certain cancers. Granted FR2706771A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9307805A FR2706771A1 (en) 1993-06-21 1993-06-21 Formula for the treatment of certain cancers.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9307805A FR2706771A1 (en) 1993-06-21 1993-06-21 Formula for the treatment of certain cancers.

Publications (2)

Publication Number Publication Date
FR2706771A1 true FR2706771A1 (en) 1994-12-30
FR2706771B1 FR2706771B1 (en) 1995-12-01

Family

ID=9448594

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9307805A Granted FR2706771A1 (en) 1993-06-21 1993-06-21 Formula for the treatment of certain cancers.

Country Status (1)

Country Link
FR (1) FR2706771A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6004927A (en) * 1994-02-02 1999-12-21 Regents Of The University Of California Method for increasing bioavailability of orally administered pharmaceutical compounds
WO2000033858A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
FR2863170A1 (en) * 2003-12-08 2005-06-10 Nicolai Christian Paul Xavier Composition for regulation and cellular regeneration in the digestive tract, useful e.g. for treating gastroenteritis or improving animal performance, comprises essential oils, shark liver oil, selenium and water
US7141363B2 (en) 1999-04-08 2006-11-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
FR2912310A1 (en) * 2007-02-13 2008-08-15 Kasan Sarl Cosmetic or pharmaceutical compositions comprise allium and citrus extracts and a combination of paullinia and theobroma extracts or a combination of a salix extract and zinc sulfate
FR3012037A1 (en) * 2013-10-23 2015-04-24 Herve Edouard Henri Jeambourquin Revertant solution based on dimethylsulfoxide and polyethylene glycol
US9789171B2 (en) 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
US10357531B2 (en) 2013-11-08 2019-07-23 Legacy Healthcare Ltd. Method for the management of cancer and cancer treatment-related comorbidities
US11219592B2 (en) 2013-10-16 2022-01-11 Legacy Healthcare (Switzerland) Sa Use of a composition for the pigmentation of hair and hairs

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US7935362B2 (en) 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2563109A1 (en) * 1984-04-18 1985-10-25 Truc Daniel Phytotherapeutic composition composed of plants containing oils, plants containing mineral salts, plants containing waxes, oxidases and mineral salts, which treats diseases of the airways, and process for preparing it
SU1572637A1 (en) * 1987-06-17 1990-06-23 Научно-Исследовательский Институт Туберкулеза Им.Ш.А.Алимова Medicinal agent for prevention side effect of antituberculous preparations
GB2238476A (en) * 1989-11-04 1991-06-05 K T Lalvani Therapeutic aquatic animal and garlic products
DE4024155A1 (en) * 1990-07-30 1992-02-06 Marcela Dipl Ing Holzhey Internal use of allicin-urotropin product - to treat bacterial, viral and fungal infections including meningitis, rabies, AIDs, tuberculosis, leprosy, plague and cancer
JPH04149135A (en) * 1990-10-09 1992-05-22 Kureha Chem Ind Co Ltd Perfume composition and perfume product therefrom

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2563109A1 (en) * 1984-04-18 1985-10-25 Truc Daniel Phytotherapeutic composition composed of plants containing oils, plants containing mineral salts, plants containing waxes, oxidases and mineral salts, which treats diseases of the airways, and process for preparing it
SU1572637A1 (en) * 1987-06-17 1990-06-23 Научно-Исследовательский Институт Туберкулеза Им.Ш.А.Алимова Medicinal agent for prevention side effect of antituberculous preparations
GB2238476A (en) * 1989-11-04 1991-06-05 K T Lalvani Therapeutic aquatic animal and garlic products
DE4024155A1 (en) * 1990-07-30 1992-02-06 Marcela Dipl Ing Holzhey Internal use of allicin-urotropin product - to treat bacterial, viral and fungal infections including meningitis, rabies, AIDs, tuberculosis, leprosy, plague and cancer
JPH04149135A (en) * 1990-10-09 1992-05-22 Kureha Chem Ind Co Ltd Perfume composition and perfume product therefrom

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CD-ROM VIDAL, O.V.P. - EDITIONS DU VIDAL, 1992, PARIS *
DATABASE WPI Section Ch Week 9107, Derwent World Patents Index; Class B04, AN 91-050090 *
DATABASE WPI Section Ch Week 9227, Derwent World Patents Index; Class B04, AN 92-223430 *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004927A (en) * 1994-02-02 1999-12-21 Regents Of The University Of California Method for increasing bioavailability of orally administered pharmaceutical compounds
US6028054A (en) * 1994-02-02 2000-02-22 The Regents Of The University Of California Method for increasing bioavailability of oral pharmaceutical compositions
US6121234A (en) * 1995-06-07 2000-09-19 Avmax, Inc. Use of essential oils to increase bioavailability of orally administered pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO2000033857A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils
WO2000033856A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
US7291650B2 (en) 1998-12-07 2007-11-06 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils
US6812258B2 (en) 1998-12-07 2004-11-02 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils
CN100448454C (en) * 1998-12-07 2009-01-07 艾科斯迈特技术公司 Cancer treatment composition and method using natural plant essential oils
US7008649B2 (en) 1998-12-07 2006-03-07 Ecosmart Techonlogies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
WO2000033858A1 (en) * 1998-12-07 2000-06-15 Ecosmart Technologies, Inc. Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US7141363B2 (en) 1999-04-08 2006-11-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7775469B2 (en) 1999-04-08 2010-08-17 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
FR2863170A1 (en) * 2003-12-08 2005-06-10 Nicolai Christian Paul Xavier Composition for regulation and cellular regeneration in the digestive tract, useful e.g. for treating gastroenteritis or improving animal performance, comprises essential oils, shark liver oil, selenium and water
US9789171B2 (en) 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
US10406217B2 (en) 2004-11-05 2019-09-10 The General Hospital Corporation Antifugetactic agents for the treatment of cancers
WO2008113912A3 (en) * 2007-02-13 2008-12-11 Legacy Healthcare Holding Ltd Novel cosmetic and/or pharmaceutical compositions and applications thereof
CN101631529B (en) * 2007-02-13 2013-01-09 传世健康护理控股有限公司 Novel cosmetic and/or pharmaceutical compositions and applications thereof
US8361522B2 (en) 2007-02-13 2013-01-29 Legacy Healthcare Holding Ltd Cosmetic and/or pharmaceutical compositions and their applications
EP2606874A3 (en) * 2007-02-13 2013-08-14 Legacy Healthcare Holding Ltd. Novel cosmetic and/or pharmaceutical compositions and uses thereof
US8652543B2 (en) 2007-02-13 2014-02-18 Legacy Healthcare Holding Ltd. Cosmetic and/or pharmaceutical compositions and their applications
FR2912310A1 (en) * 2007-02-13 2008-08-15 Kasan Sarl Cosmetic or pharmaceutical compositions comprise allium and citrus extracts and a combination of paullinia and theobroma extracts or a combination of a salix extract and zinc sulfate
US11219592B2 (en) 2013-10-16 2022-01-11 Legacy Healthcare (Switzerland) Sa Use of a composition for the pigmentation of hair and hairs
FR3012037A1 (en) * 2013-10-23 2015-04-24 Herve Edouard Henri Jeambourquin Revertant solution based on dimethylsulfoxide and polyethylene glycol
US10357531B2 (en) 2013-11-08 2019-07-23 Legacy Healthcare Ltd. Method for the management of cancer and cancer treatment-related comorbidities

Also Published As

Publication number Publication date
FR2706771B1 (en) 1995-12-01

Similar Documents

Publication Publication Date Title
FR2706771A1 (en) Formula for the treatment of certain cancers.
Sellami et al. Herbal medicine for sports: a review
de La Cruz et al. Hot and cold: Medicinal plant uses in Quechua speaking communities in the high Andes (Callejón de Huaylas, Ancash, Perú)
OKWU The potentials of Ocimum gratissimum, Penrgularia extensa and Tetrapleura tetraptera as spice and flavouring agents
Carrió et al. Ethnobotany of medicinal plants used in eastern Mallorca (Balearic Islands, Mediterranean Sea)
Njoku et al. Phytochemical and nutrient evaluation of Spondias mombin leaves
Nedelcheva Medicinal plants from an old Bulgarian medical book
Makni et al. Hypolipidemic and hepatoprotective seeds mixture diet rich in ω-3 and ω-6 fatty acids
Bulut et al. The preliminary ethnobotanical study of medicinal plants in Uşak (Turkey)
Khan et al. Comprehensive nutrients analysis of rhizomes of Polygonatum verticillatum.
Nosirova Medicinal properties of olives
Oko et al. Nutritional and Phytochemical compositions of the leaves of Mucuna poggei
Awol Nutrient, mineral and bioactive constituent evaluation of bamboo shoots grown in Masha area, South-West of Ethiopia
Katana Effectiveness of pomegranate Punica Granatum L. fruit extract on the sexual function in rats
Rogers Fireweed–a treasured medicine of the boreal forest
Celia et al. Effect of Digestarom® dietary supplementation on the reproductive performances of rabbit does: preliminary results
Meral et al. Serum copper, zinc, manganese, and magnesium status of subjects with chronic fluorosis
Alkış et al. Investigation of medicinal plants used for weight loss in herbal markets of şanlıurfa, birth place of Abraham, Turkey
Mitrofanov et al. Drone Brood: Food and Apitherapeutic Agent
Chinonye et al. Minerals and phytochemical constituents of Mangifera indica seed kernel obtained from Eastern Nigeria
Ahmad et al. Ethnobotanical aspects of some traditional medicinal plants
Effoe et al. Assessment of the nutritional potential of Amaranthus spinosus L.(Amaranthaceae) and Tridax procumbens L.(Asteraceae), two leafy vegetables from the Maritime region of Togo
Hadi Usage of fenugreek as appetite to increase the weights of children aged (3-5)
FR2584929A1 (en) Nutritional supplement composition based on Fraxinus excelsior leaves for nature-cure therapy
RU2448683C1 (en) Milk-wax walnut and buckeye ointment

Legal Events

Date Code Title Description
ST Notification of lapse